Shares of Tandem Diabetes Care (NASDAQ:TNDM), a medical equipment company that focuses on products for diabetics, such as insulin pumps, climbed 17.1% in December, according to data provided by S&P Global Market Intelligence. The stock was as low as $122.21 on Dec. 2, but steadily climbed throughout the month, and was as high as $153.95 on Dec. 30. Over the past year, the stock has risen more than 30%, and it has a 52-week low of $76.19 and a high of $155.86.
There are plenty of reasons lately for investors to get behind this stock. The company issued guidance for annual revenue between $685 million and $695 million, representing growth of 37% to 39%, in 2021. Through the first nine months of the year, the company reported earnings per share (EPS) of $0.08, compared to an EPS loss of $0.85, year over year. The most important thing is that the company increased pump shipments in the third quarter by 43% over the same period last year, meaning it is setting itself up for long-term revenue growth as the pumps lead to additional sales of cartridges and renewal pumps, Tandem said in its third-quarter earnings call.
The company makes one of the smallest insulin pumps on the market, the t:slim X2, and it has been gaining market share, along with its Control-IQ technology, which is compatible with smartphone apps. Since Control-IQ’s launch in the U.S. in the first quarter 2020, the number of patients using the technology has risen to 200,000, the company said. Tandem said it expects to end 2021 with a compound annual growth rate (CAGR) of 54% in revenue since 2018, plus a increase of 500 basis points in gross margin and 2,300 basis points in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) over that time period.
And there’s still plenty of room to grow. According to statistics from the International Diabetes Federation, there are 537 million people ages 20 to 79 living with diabetes, and that number is expected to increase to 783 million by 2045. In the United States, it is the seventh leading cause of death, according to the Centers for Disease Control and Prevention, although it says that the number of diabetes-related deaths is likely underreported. The company’s insulin pumps work well with modern continuous glucose monitoring systems that are becoming increasingly popular because they work without the need for needles.
Tandem’s stock, with a price-to-earnings ratio of 430.08, certainly isn’t cheap, so to continue to be a good investment, the healthcare stock needs to continue its run of revenue growth. Over the past five years, quarterly revenue has risen 846.6%. The company believes that the entire diabetes market is ready for greater adoption of insulin pumps.
There’s little question that diabetes equipment such as insulin pumps is a growth industry, but there’s also plenty of competition, so Tandem’s continued expansion will depend on its innovation as the pumps become smaller and more sophisticated.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.